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Abstract
Infections that cause significant nervous system morbidity globally include viral (for example, 
HIV, rabies, Japanese encephalitis virus, herpes simplex virus, varicella zoster virus, 
cytomegalovirus, dengue virus and chikungunya virus), bacterial (for example, tuberculosis, 
syphilis, bacterial meningitis and sepsis), fungal (for example, cryptococcal meningitis) and 
parasitic (for example, malaria, neurocysticercosis, neuroschistosomiasis and soil-transmitted 
helminths) infections. The neurological, cognitive, behavioural or mental health problems caused 
by the infections probably affect millions of children and adults in low- and middle-income 
countries. However, precise estimates of morbidity are lacking for most infections, and there is 
limited information on the pathogenesis of nervous system injury in these infections. Key research 
priorities for infection-related nervous system morbidity include accurate estimates of disease 
burden; point-of-care assays for infection diagnosis; improved tools for the assessment of 
neurological, cognitive and mental health impairment; vaccines and other interventions for 
preventing infections; improved understanding of the pathogenesis of nervous system disease in 
these infections; more effective methods to treat and prevent nervous system sequelae; operations 
research to implement known effective interventions; and improved methods of rehabilitation. 
Research in these areas, accompanied by efforts to implement promising technologies and 
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therapies, could substantially decrease the morbidity and mortality of infections affecting the 
nervous system in low- and middle-income countries.
Recent improvements in the detection of infectious organisms that can affect the nervous 
system has led to the realization that a substantial proportion of chronic neurological, 
cognitive and behavioural disease may actually have an acute and preventable origin. 
Infectious organisms may infect the nervous system directly, as in rabies and bacterial 
meningitis, or may cause neurocognitive disorders in the absence of direct infection of the 
nervous system, as in malaria or hookworm infection. This Review identifies global research 
priorities for infections that affect the nervous system, with the ultimate goal of stimulating 
research in these priority areas to substantially reduce morbidity associated with nervous 
system infections worldwide.
METHODS
For this Review, we chose illustrative infections that cause considerable nervous system 
morbidity in children and adults in low- and middle-income countries (LMICs). These 
infections are examples and are not meant to be exhaustive. Estimates of infection global 
frequency and types of nervous system involvement were obtained through PubMed 
searches using the infection name and were accompanied by any of the following terms: 
neurologic, nervous system, cognition, cognitive, development, neurodevelopment, 
impairment, deficit, sequelae, brain injury, brain damage, mental health, behavioral or 
neuropathy. If available, World Health Organization (WHO) documents were also reviewed 
for each disease. The authors came to a consensus on the key research priority areas, on the 
basis of a literature review and research experience.
INFECTIONS AFFECTING THE NERVOUS SYSTEM
The global distribution, frequency and types of neurological, cognitive and mental health 
disorders associated with key infections are presented in Table 1. For classification 
purposes, infections are reviewed according to type of microorganism (virus, bacteria, 
fungus or parasite) in the sections that follow. However, microorganisms within a group (for 
example, the viruses HIV and rabies) can affect the nervous system in as varied a manner as 
microorganisms of different groups (for example, the virus HIV and the malaria-causing 
parasite Plasmodium falciparum).
Viral infections
Worldwide, rabies and Japanese encephalitis virus (JEV) are responsible for an estimated 
annual mortality of 60,000 and 17,000 people, respectively1,2. Cases of JEV encephalitis are 
restricted to Asia, whereas rabies is a scourge throughout Southeast Asia, Africa and Latin 
America and occurs, although less frequently, in other areas worldwide. Rabies and herpes 
simplex virus (HSV) encephalitis, which is also present worldwide, lead to high mortalities 
without treatment3. JEV has variable mortality, depending, in part, on the infected 
individual's age. Among survivors, long-term cognitive or neurological impairment is 
present in as many as 70% of those with HSV encephalitis4 and 30–50% of those with JEV 
encephalitis5. Most cases of JEV infection (as opposed to encephalitis) are asymptomatic or 
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mildly symptomatic and require no treatment6, but the long-term neurocognitive 
consequences of asymptomatic or mildly symptomatic JEV infections are unknown.
Varicella zoster virus (VZV), the cause of chickenpox, can, like other herpesviruses, 
establish a latent infection. Reactivation is usually owing to suppression of cell-mediated 
immunity, most commonly age-related immunosenescence. Central nervous system (CNS) 
reactivation is relatively uncommon, but reactivation in a dorsal root ganglion can lead to 
herpes zoster, which is associated with debilitating chronic pain7. Herpes zoster is the single 
most common infection of the nervous system, with an estimated one million new cases 
each year in the United States alone8. There is little data on nervous system VZV infection 
in LMICs.
Congenital cytomegalovirus (CMV) infection is the most common acquired cause of hearing 
loss in children in the United States9. The percentage of the population testing positive for 
CMV is higher in LMICs than in high-income countries, but the incidence of congenital 
CMV infection and of symptomatic CNS disease and hearing loss in most LMICs remains 
almost unknown10.
Dengue, and to a lesser extent chikungunya, viruses will probably become leading global 
causes of arboviral encephalitis in the next decade2,11,12. Although encephalitis is present in 
only a fraction of those infected with dengue virus, the large number of dengue infections 
worldwide could lead to hundreds of thousands of encephalitis cases (Table 1).
HIV and opportunistic infections
In 2012, an estimated 2.3 million people were infected with HIV, and 1.6 million died of 
AIDS-related illnesses worldwide13. HIV-associated neurological syndromes are classified 
as primary HIV infection, secondary or opportunistic infection, and treatment-related 
neurological disease. Most often, primary HIV infection causes acute aseptic (viral) 
meningitis or meningoencephalitis (MEC). HIV-associated neurocognitive disorder 
(HAND) is a neurodegenerative condition characterized by cognitive, motor and behavioural 
abnormalities that is becoming more common with an increase of HIV in people older than 
50 years14. In LMICs, where only one third of patients requiring highly active antiretroviral 
therapy (HAART) receive it, the opportunistic infections cryptococcal meningitis, 
tuberculous meningitis, cerebral toxoplasmosis, progressive multifocal leukoencephalopathy 
and CNS cytomegalovirus infection remain common15.
The widespread implementation of combination antiretroviral therapy (cART) has changed 
the presentation, manifestation and epidemiology of many conditions and opportunistic 
infections, owing to immune reconstitution syndrome and increased prevalence of cognitive 
impairment and neuropathy with additional morbidities in patients who are now living 
longer16. The epidemiology and neurological outcomes of HIV infection are also affected by 
underlying malnutrition and variations in endemic pathogens.
Cryptococcal meningitis is a leading cause of mortality in LMICs where access to 
antiretroviral therapy is limited17. Most cases occur in sub-Saharan Africa, followed by 
South and Southeast Asia18. Seroprevalence for Toxoplasma gondii in people with HIV 
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ranges from 10% to 80% with the highest proportions in African countries19, and cerebral 
toxoplasmosis is the most common cerebral mass lesion in patients with AIDS.
Bacterial infections
The most common bacterial infections affecting the nervous system are sepsis and 
meningitis in neonates; bacterial meningitis due to Streptococcus pneumoniae, Haemophilus 
influenzae type b and Neisseria meningitidis in children and adults; and tuberculous 
meningitis in children and adults.
Neonatal meningitis and neonatal sepsis are associated with long-term neurological and 
cognitive impairment20; primarily impairment of hearing, vision or motor function; cerebral 
palsy; and epilepsy. In LMICs, it is estimated that 23% of neonates who have survived 
meningitis sustain moderate to severe neurodevelopmental impairment21. Staphylococcus 
aureus, Gram-negative infections, including Escherichia coli, Klebsiella pneumoniae, 
Acinetobacter, non-typhoidal Salmonella and group B Streptococcus, are the leading causes 
of neonatal sepsis and meningitis in most LMICs22–24. Recent reports from Africa and India 
suggest an alarming increase in drug resistance among Gram-negative organisms infecting 
neonates24,25.
In children and adults in high-income countries, bacterial meningitis due to S. pneumoniae, 
H. influenzae type b and N. meningitidis has decreased dramatically following immunization 
with conjugate vaccines26. However, availability of these vaccines in LMICs is variable, and 
bacterial meningitis still affects 1.2 million individuals annually26, causing neurocognitive 
sequelae in 23% of affected children. Steroids as an adjunctive therapy have reduced 
neurological sequelae in high-income countries, particularly in adults, but have shown no 
benefit in LMICs27. Factors such as organism strain, co-infections, adjunctive and 
supportive therapies, and underlying conditions such as poor nutrition that can affect 
immune response often differ between high-income countries and LMICs, and may play a 
part in the different results seen in some clinical trials.
Tuberculous meningitis (TBM) occurs in around 1% of all cases of tuberculosis, but is the 
most severe form of extrapulmonary tuberculosis, resulting in death or severe disability in 
about 50% of those with the disease28. Bacterial meningitis, and particularly TBM, can 
result in hydrocephalus, which is often difficult to treat in LMICs because neurosurgeons are 
typically not available and the supplies for ventriculoperitoneal shunt placement are often 
not present or very limited.
The WHO estimated that approximately 10.6 million new cases of syphilis occurred in 2008 
(ref. 29), but precise estimates of the incidence of neurosyphilis are not available.
Parasitic infections
Malaria in humans is caused by one of five Plasmodium species, but neurological 
disabilities are most frequently associated with Plasmodium falciparum. Although P. 
falciparum does not directly infect brain tissue, severe infection can lead to coma. One in 
four children with cerebral malaria develops long-term cognitive impairment30, and recent 
studies suggest that children with severe malarial anaemia also have long-term cognitive 
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impairment31. Behavioural problems and epilepsy are other long-term consequences of 
cerebral malaria32. Children with repeated episodes of uncomplicated malaria have motor 
and cognitive problems33. The mechanisms by which malaria leads to neurocognitive 
problems are not fully defined, and the neurocognitive burden of malaria owing to other 
Plasmodium species has not been characterized.
Neurocysticercosis, which is endemic in areas with poor pig management practices and 
sanitation, occurs when the larval stages of Taenia solium infect the brain. In LMICs in 
which neurocysticercosis is endemic, it is the leading identified cause of seizures. The 
proportion of larval infections migrating to the brain is unknown, but some individuals with 
neurocysticercosis never show neurological symptoms34. Neurocysticercosis can be fatal, 
most often following complications of surgery to treat the hydrocephalus associated with 
intraventricular or subarachnoid neurocysticercosis, but overall mortality estimates have 
been difficult to obtain35.
Neuroschistosomiasis results from the migration of schistosome eggs or worms to the brain 
or spinal cord, and may occur following infection with Schistosoma japonicum, Schistosoma 
mansoni or Schistosoma haematobium. Brain involvement may occur in the acute phase 
(acute schistosomal encephalopathy) or in the chronic phase (cerebral schistosomiasis or 
pseudotumoral encephalic schistosomiasis). The spinal cord may also be involved, often 
leading to hemiparesis36. CNS symptoms and epilepsy are reported to occur in 2.6% and 
2.1% of S. japonicum infections, respectively37. Neuroschistosomiasis can be fatal, 
especially in its tumour-like form when it affects the cerebellum, but accurate mortality rates 
are unavailable38.
Soil-transmitted helminths (STH) affect millions, most frequently children. Determining the 
part played by STH in cognitive impairment of children is complicated because STH 
infection is associated with many confounders, but data that support a role for STH in 
neurobehavioural outcomes include a study showing that infants and children under 5 years 
of age with anaemia and STH infection show disturbed social and emotional behaviour. 
Another study showed that treating school-aged children with antiparasitic drugs and iron 
supplementation improved attention, memory and processing speed39.
GLOBAL RESEARCH PRIORITIES
Prevention of infections that affect the nervous system is the highest research priority, as 
complete prevention of infection removes all risk of nervous system sequelae. However, 
treatment of nervous system sequelae and rehabilitation of individuals with nervous system 
morbidity are also important for the millions who currently live with the nervous system 
effects of infections. Prevention and treatment of infections that affect the nervous system 
requires the identification of the pathogens responsible, the pathogen reservoirs and the 
potential points at which the pathogen life cycle can be interrupted. Table 1 lists specific 
pathogens, their known nervous system manifestations, and current knowledge gaps 
regarding incidence and long-term sequelae for each pathogen. Table 2 outlines whether 
specific interventions (vaccines, control of zoonotic reservoirs or vector populations, and 
treatment) are available for each pathogen. Table 3 provides a summary of global research 
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priorities for infections that affect the nervous system. These research priorities are 
discussed in more detail below.
Diagnosis
Improved diagnosis lies at the heart of all research priorities for infections that affect the 
nervous system because all other research areas depend on accurate infection diagnosis. 
Improved diagnosis requires better tests to detect infection, better clinical diagnostic 
algorithms to detect infection and better tools to assess the nervous system effects of 
infection, including cognitive and mental health sequelae.
Affordable, easy-to-use, rapid diagnostic assays — preferably point-of-care — that can 
identify infections affecting the nervous system are a high priority. This includes diagnostic 
tests for infections that directly infect nerve cells and those that do not (for example, malaria 
and STH). For infections that affect the CNS, field diagnoses are needed to identify when 
the infection has entered the CNS. Serological assays are available to detect 
schistosomiasis36 and cysticercosis, but these tests are not specific for CNS infection, and 
the blood–brain barrier may prevent the detection of antigens in serum40. In the case of 
bacterial, fungal or viral CNS infections, although lumbar puncture to obtain cerebrospinal 
fluid is a routine procedure at many centres in LMICs, most lack the capacity for standard 
bacterial, fungal or viral cultures, let alone more sophisticated testing such as PCR, which is 
essential for detecting many viral infections. Even in high-income countries with advanced 
molecular diagnostics, an aetiological agent is identified in less than half of individuals with 
encephalitis. Because many cases of idiopathic encephalitis are probably caused by viruses 
still to be characterized, the development of metagenomic and high-throughput screening 
techniques for viral detection is a research priority, with the goal of eventually developing 
low-cost diagnostic point-of-care assays for the pathogens identified. For certain CNS 
infections, notably neurocysticercosis, neuroschistosomiasis, CNS tuberculosis and CNS 
toxoplasma infection, neuroimaging with CT scans or MRI is needed to make a diagnosis. 
Although availability of neuroimaging is becoming more widespread, many facilities in 
LMICs still lack these costly imaging modalities, underscoring the need for research on 
simple, accurate, low-cost, point-of-care diagnostic tests for detecting infections that affect 
the nervous system.
One example of how improved diagnostic tools can have an impact is a study41 from India 
in which a simple diagnostic algorithm and basic treatment for neonatal sepsis, all 
performed by village health workers, led to a 63% reduction in neonatal mortality among 
preterm infants41. Simple algorithms for other infections that affect the nervous system, 
coupled with the ability to provide effective therapy following diagnosis, or appropriate 
referral for screening algorithms, have the potential to substantially reduce morbidity and 
possibly mortality from these infections. Improved cross-cultural measurements of 
neurodevelopment and mental health are a key research priority, and reviewed in the article 
in this collection on child neurodevelopment (see page S155).
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Epidemiology and primary prevention
The lack of affordable, non-invasive, rapid diagnostics for infection and nervous system 
effects of infection limits our ability to quantify the burden of infection-related nervous 
system disability (Table 1). Well-designed studies of disease epidemiology are also required 
for the accurate measurement of disease incidence, and of the type and duration of nervous 
system sequelae of infection.
A challenge to the estimation of infection-related nervous system disease is that the 
symptoms these infections result in, such as epilepsy, hemiparesis or cognitive impairment, 
are included as ‘chronic diseases’ in global burden estimates. Careful epidemiological 
assessment could lead to the more accurate attribution of a portion of ‘chronic disease’ to its 
infectious component. For example, the Global Burden of Disease Study 2010 (ref. 42) 
attributed some of the disability-adjusted life years of epilepsy to neurocysticercosis. This 
infection is also associated with stroke43, which was ranked third in terms of disability-
adjusted life years in 2010 (ref. 42), but none of this burden was attributed to 
neurocysticercosis owing to lack of data. Thus the true burden of nervous system disease 
owing to neurocysticercosis was probably significantly underestimated.
The most cost-effective method of preventing infection is immunization, discussed in the 
section on vaccines below. For infections for which there is no immunization, or for which 
immunization is not highly successful, research is required on sustainable preventive 
methods. For vector-borne illness, for example, insecticide-based interventions such as 
insecticide-treated bed nets have reduced malaria incidence and mortality in many areas44. 
But increasing pyrethroid resistance45 highlights the need for ongoing research even for 
interventions with documented past success.
Pathogenesis
Disease pathogenesis may be the most neglected research focus of infection-related nervous 
system disease in LMICs. Although some studies on the pathogenesis of infection-related 
nervous system disease in individuals in high-income countries are available46,47, far fewer 
studies of pathogenesis have been conducted in individuals from LMICs. Even in high-
income countries, studies of infection pathogenesis often use animal models, which may 
incompletely recapitulate the host response in humans. The host immune response probably 
contributes to both defence against invading pathogens and subsequent damage to the 
nervous system48, but the type and role of specific cells in the immune response at different 
infection stages are poorly described. Similarly, it is often unclear which antigens or 
components of the infecting organism confer neurovirulence. The roles of innate immunity, 
the microbiome, and co-infection with endemic pathogens, including HIV, in contributing to 
infection-related nervous system disease are also poorly understood (Box 1). Without an 
understanding of the pathogenesis of infection-related nervous system disease, it is difficult 
to rationally plan for adjunctive interventions to prevent or reduce nervous system injury. 
Although adjunctive interventions have been elusive, those proven successful (for example, 
steroid treatment in tuberculous meningitis49) have made a major difference in improving 
neurocognitive and behavioural outcomes. An understanding of the development and types 
of protective immune responses to antigens or antigenic variants of a pathogen is also 
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fundamental to the development of vaccines, which are, in most cases, the most cost-
effective method of preventing infection.
Vaccine development
Vaccines are available to prevent the neurological complications of measles, mumps, 
rubella, poliomyelitis and varicella virus as well as H. influenzae type b, S. pneumoniae and 
N. meningiditis. Effective vaccines are also available for rabies and Japanese encephalitis. 
Together, these vaccines have saved millions of lives as well as prevented long-term 
nervous system complications in millions of children and adults.
Research priorities for vaccine development include the utilization of disease immunology, 
epidemiology and pathogenesis studies to develop safe, effective vaccines, and the 
performance of phase I, II and III trials to determine vaccine efficacy and safety in humans. 
In P. falciparum malaria, for example, knowledge of antibody and T-cell immune responses 
to circumsporozoite protein (CSP)50,51 led to phase I and II trials of the CSP-based RTS,S 
vaccine52. These successful trials led to the recently completed phase III trials of RTS,S53. 
This constituted a major advance in the vaccine field because they established RTS,S as the 
first successful vaccine in humans against a parasite. However, the relatively modest 
efficacy (30–50%) of RTS,S was not surprising in light of the known complexity of the 
human immune response to P. falciparum in endemic populations. Hence, work continues 
on the development of more effective vaccines. Understanding the human immune response 
to P. falciparum infection will be key to the development of vaccines with improved 
efficacy and safety.
Treatment
Treatment with antimicrobials is designed to clear infection or reduce infectious load, 
decrease disease severity, and ideally to provide a degree of secondary prevention against 
the nervous system effects of the infection. For viral infections, with the exception of HSV 
and HIV, there is often no specific treatment. Even for HSV encephalitis, standard treatment 
(intravenous acyclovir) is unavailable in many parts of the world. Cost effectiveness and 
stakeholder analyses could be useful in influencing policymakers to increase availability of 
antiviral treatment. For HIV-associated opportunistic infections such as cryptococcal 
meningitis, development of therapies that do not rely on intravenous administration is a 
priority because capacity for intravenous medication is limited in many LMICs, particularly 
in rural areas. There is also a need for improved access to new assays that detect 
antiretroviral therapy resistance (for example, the oligonucleotide ligase assay), as these can 
guide cART treatment. For many parasitic infections, antiparasitic medications are available, 
but their efficacy in reducing the neurological or cognitive sequelae remains uncertain. For 
this reason, as noted in the pathogenesis section, development of adjunctive therapies that 
target prevention or reduction of nervous-system injury is an important research priority.
Development of low-cost, low-toxicity antimicrobials that work against drug-resistant 
pathogens is a research priority for several infections, including tuberculous meningitis and 
neonatal sepsis caused by multiresistant Gram-negative infections. Qualitative studies to 
better understand medical non-compliance, and to develop innovative solutions to reduce 
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non-compliance through newer technologies, such as mobile devices that support medical 
and public-health practice, are also needed.
Finally, there is a need for multicentre clinical research trials with sufficient sample sizes to 
provide definitive answers on the efficacy of specific interventions. For example, where 
smaller trials had failed, the Cryptococcal Optimal Anti-Retroviral Timing (COAT) trial 
conducted in Uganda and South Africa successfully determined that deferred initiation of 
anti-retroviral therapy in individuals with HIV until 5 weeks after treatment of cryptococcal 
meningitis improved survival54. This study finding is likely to change international 
guidelines.
Physical, occupational and cognitive rehabilitation
Whereas physical, occupational and cognitive rehabilitation for individuals with sequelae of 
CNS infections are routine in developed countries, such interventions are limited in LMICs 
owing to a lack of trained personnel and prohibitive costs. Thus, research on how to build 
capacity for rehabilitation and how to support it in the context of LMICs is required. 
Rehabilitation for cognitive impairment can be successfully implemented in the community 
using locally available resources or in a tertiary institution using advanced methods. In the 
community, home stimulation, parenting education and support, and provision of financial 
support or nutritional support for children enrolled in early child development centres have 
shown some benefit in improving children's cognition55,56. Interventions that target both the 
carer and the child are more effective than those that include either one56. In tertiary centres, 
computer-based cognitive training programmes have proven effective in improving 
cognition in African children surviving CNS infections57,58. These cognitive training 
programmes can target specific disabilities; however, they are in their early stages and more 
research is required to determine the most cost-effective implementable and sustainable 
programmes for LMICs.
Operations and implementation research
Operationalization and implementation of known effective interventions is another research 
priority area. Vaccines for S. pneumoniae and N. meningiditis are highly effective and have 
been implemented in some LMICs, but these vaccine-preventable infections continue to 
affect more than 1 million people each year. Thus, in addition to increased investment in the 
basic science of vaccines, a major research priority is the assessment of methods to support 
and implement widespread vaccination in LMICs.
Another example is implementation research related to effective prenatal, perinatal and 
neonatal care, which would decrease neonatal sepsis. Assessment of effective methods for 
non-physician health workers to provide medical and preventive care to mothers and 
newborns in LMICs are needed59. The recent increase in neonatal infection with multi-drug-
resistant Gram-negative organisms in LMICs24,25 makes prevention of neonatal sepsis an 
even greater research priority. Rapid diagnostics and treatment interventions that are 
successful in field trials also require implementation research for successful wide-scale 
adoption and appropriate use.
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Capacity building
Capacity building within LMICs is key to the successful reduction or elimination of nervous 
system complications of infection. The Review on research capacity building in this 
collection addresses this topic in depth (see page S207). Research priorities specifically in 
the area of infection-related nervous system morbidity include an increase in the number of 
clinicians and researchers in infectious disease, neuroscience, neurology and mental 
health60, and the dedication of a portion of LMICs health budgets to infectious disease and 
mental and neurological health61 . Research training grants and collaborative research 
between partners in LMICs and high-income countries specifically in the area of infection-
related neurocognitive impairment can also help to build human resource capacity. Physical 
infrastructure is another priority; without space for laboratories, diagnostic equipment or 
research clinics, surveillance cannot be performed and information to guide interventions to 
reduce the burden of these infections cannot be generated. With improved human resource 
capacity and infrastructure, the development of effective screening instruments, prevention 
and treatment, and increased government support to address these infections are more likely 
to be achieved. Box 2 provides examples of capacity building in Peru and Uganda in the 
area of infections that affect the nervous system. This was enabled by Fogarty International 
Center grants for collaborative US–LMICs partnerships in these countries.
CONCLUSIONS
In the past two decades, an increasing body of evidence implicates infection as a cause of 
substantial nervous system morbidity in high-income countries and LMICs. The burden is 
particularly high in LMICs, where infections such as HIV (and associated opportunistic 
infections), HSV, dengue, bacterial and tuberculous meningitis, malaria, neurocysticercosis, 
STH, schistosomiasis and other infections affect billions of people annually, and cause 
substantial neurological morbidity in those individuals. The involvement of the nervous 
system in infections is often first recognized in LMICs where the prevalence of these 
infections is higher and where new infections often emerge. Research conducted in these 
countries can contribute to prevention and cure before these infections become globalized. 
Research is needed in multiple areas to determine the true burden of disease and to develop 
point-of-care diagnostic assays for diagnosing infection, vaccines and other interventions for 
preventing infections; to improve our understanding of the pathogenesis of nervous system 
disease in these infections; to develop better tools for the assessment of neurological, 
cognitive and mental health impairment; to develop more effective treatments and 
preventions for nervous system sequelae, to improve the implementation of successful 
interventions, and to improve rehabilitation for those with long-term neurocognitive or 
mental health disabilities. Good research studies in these areas, accompanied by equally 
strong efforts to implement promising technologies and therapies, could substantially 
decrease the morbidity and mortality of infections affecting the nervous system in LMICs.
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BOX 1 | EMERGING RESEARCH AREAS
Diarrhoeal disease
Diarrhoea is a leading cause of mortality in children living in low- and middle-income 
countries (LMICs)62. Most of these deaths occur in Africa, Southeast Asia and in eastern 
Mediterranean countries63. In 2010, it is estimated that there were 1.731 billion episodes 
of diarrhoea worldwide of which 36 million progressed to severe diarrhoea and 700,000 
episodes resulted in death64. Its occurrence in the first 2 years of life is associated with an 
8 cm decrease in height and a 10 point drop in IQ by the time children are around 7 to 9 
years old65. The mechanism by which diarrhoea affects cognition is not clear, but it could 
be through the effect of diarrhoea on stunting, which in turn predicts future cognition66. 
However, during diarrhoea-free periods in the first 2 years of life, children experience 
catch-up growth and may return to their original growth trajectories67. This highlights the 
importance of effective interventions for diarrhoea to sustain the child's developmental 
potential. The high frequency of diarrhoea episodes during this critical developmental 
stage and the large number of cases makes diarrhoea a major public health concern for 
child development.
The microbiome
Although it has been clearly demonstrated that pathogenic microbes can cause brain 
disorders, there is increasing evidence that the microbial population harboured in the 
human body, termed the human microbiome, can as a whole influence brain activity68. 
Recent clinical studies among healthy subjects suggest that treatment with a probiotic is 
associated with reduced symptoms of stress and depression69. There is also evidence of 
associations between the microbiome and neurological diseases, such as multiple 
sclerosis and autism spectrum disorder (ASD)70. In a recent study using a mouse model 
of ASD, treatment with probiotics alleviated some behavioural symptoms of the 
disorder71. The composition of the human microbiome shows marked differences 
between countries72 and comparative research conducted in high-income countries and 
LMICs could lead to a better understanding of the part played by the human microbiome 
in brain disorders, and possible treatment of these disorders with factors that favourably 
alter the microbiome.
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BOX 2 | CAPACITY BUILDING IN UGANDA AND PERU
Uganda
The Severe Malaria Research Centre in Uganda is an example of how collaborations 
between local and foreign scientists, with support from the Fogarty International Center, 
has built a hub for research excellence. Through a National Institutes of Health (NIH) 
R21 exploratory research grant in 2004, local scientists developed research capacity by 
involvement in research studies, and grant and manuscript writing. This has since led to 
further NIH grants (four R01 grants, a U01 grant, a D43 grant and two R34 grants) as 
well as multiple grants from other agencies. Ugandan and US faculty are principal 
investigators on these grants. A book on neuropsychology of African children and more 
than 30 research papers have been published from these projects so far. Ugandan 
scientists and physicians have obtained faculty positions in Makerere University, 
Kampala. The infrastructure that has been built includes high-speed Internet connectivity 
for research offices and faculty members, a laboratory, a data room and a grants 
management office. With the infrastructure in place, this centre is now providing training 
for many Ugandan and US students and researchers at all levels of training, from 
undergraduates to post-doctoral fellows and faculty.
Peru
Through the Fogarty International Center NIH R21 and R01 grants in Peru, a network of 
neurologists who are engaged in brain-disorder research has been developed throughout 
the country. Trainee alumni of this network now serve as collaborators on emerging 
research and training activities in both infectious and chronic diseases of the nervous 
system (such as cerebrovascular diseases). The 2 sites in Lima have been scaled up to 12 
hospitals and 2 universities in 3 Peruvian regions. Capacity building of individuals was 
provided through workshops, hybrid virtual/in-person certificate courses, as well as 
medium- and long-term training in Seattle and Peru. An initial mentor-training workshop 
developed into a growing network of mentors, three of whom have been awarded 
Clayton–Dedonder Mentorship Fellowships by the Fogarty International Center and have 
started institutionalization of mentor training programmes at three institutions in Lima. 
Those who received the R21 and R01 grants in the past are now experienced researchers 
who are leading the development of research in new areas, such as neurogenetics 
research and the development of a cerebrovascular diseases research training programme. 
Research supported by these awards resulted in 26 peer-reviewed publications and book 
chapters. Programme alumni are becoming leaders in brain research and are mentoring 
the newest wave of young neurologists and neuroscientists.
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Table 1
Neurocognitive and mental health consequences of major infectious diseases that affect the nervous system.
Infectious disease Regions affected Estimated 
prevalence or 
annual 
incidence of 
infection
Health consequences
Neurological Cognitive Mental health
VIRAL
Arboviruses
Dengue virus Global, most 
common in 
South Asia, 
Africa and Latin 
America
390 million 
(95% CI, 
284-528 
million)
• Meningitis, 
meningoencephalitis, 
encephalitis, seizures, 
Guillain-Barré 
syndrome, neuralgic 
amyotrophy, 
hypokalaemic 
paralysis, and dengue 
myositis
• In one cohort, 
dengue had 
neurological 
manifestations in 
9.3% of children and 
adults
• There is limited 
information about 
long-term sequelae in 
dengue, but there is 
evidence of 
significant long-term 
neurological 
complications
• Not studied Case reports of mania 
and depression
Chikungunya virus Global, most 
common in 
South Asia, 
Africa and Latin 
America
33,000-93,000 • Encephalitis, febrile 
seizures, 
meningismus, 
myelopathy or 
myeloneuropathy
• Not studied Not studied
Japanese encephalitis Southeast Asia 35,000-50,000 • CNS complications 
during the acute 
illness include 
delirium, seizures, 
axial rigidity, 
extrapyramidal signs, 
cranial nerve palsies, 
ataxia, paraplegia and 
segmental sensory 
disturbances
• Among 
survivors, 30-50% 
have significant 
neurological, 
cognitive or 
psychiatric 
sequelae
Among survivors, 
30-50% have 
significant 
neurological, 
cognitive, or 
psychiatric sequelae
Rhabdoviruses
Rabies Global, greatest 
in sub-Saharan 
Africa, Southeast 
Asia and Latin 
America
60,000 
(probably an 
underestimate)
• Severe encephalitis, 
which is almost 100% 
fatal
• Fatal Fatal
Herpesviruses
HSV encephalitis Global Present in all 
countries where 
HSV testing has 
been performed, 
but no reliable 
global estimates
• If untreated, as in 
most LMICs, there is 
a high fatality rate for 
HSV-1 (around 70%), 
lower (around 15%) 
if treated. Long-term 
neurological 
complications occur 
in around 70% of 
adult survivors, 
including seizure 
• In one study of 
adult survivors, 
long-term 
cognitive sequelae 
included memory 
impairment (69%)
Personality or 
behavioural 
impairment in 45% of 
adult survivors
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Infectious disease Regions affected Estimated 
prevalence or 
annual 
incidence of 
infection
Health consequences
Neurological Cognitive Mental health
disorder and 
hemiparesis. In one 
cohort, neurological 
sequelae occurred in 
63% of infections in 
children, including 
seizures in 44% and 
developmental delays 
in 25%
VZV Global No reliable 
global estimates
• CNS: stroke, 
meningoencephalitis, 
myelitis
• PNS (more 
common): herpes 
zoster with chronic 
pain
• Very limited 
studies with 
conflicting results
Major depression
Congenital cytomegalovirus Global 0.6-0.7% of live 
births in high-
income 
countries and 
1-5% of live 
births in LMICs
• Most common non-
hereditary cause of 
hearing loss in 
children in the United 
States
• There are no reliable 
estimates for 
frequency of hearing 
loss due to the 
infection in most 
LMICs
• Symptomatic 
infection, seen in 
10-15% of 
congenitally 
infected children, 
is associated with 
significant global 
developmental 
delay in around 
50% of affected 
children
Behavioural problems
HIV-related
HIV Global, greatest 
burden in sub-
Saharan Africa 
and Asia
Annual 
incidence 
estimate is 2.3 
million (95% 
CI, 1.9-2.7 
million) with 34 
million people 
living with HIV/
AIDS 
worldwide, of 
whom 23 
million live in 
sub-Saharan 
Africa and 3.5 
million live in 
Southeast Asia
• HIV associated 
opportunistic 
infections, aseptic 
meningitis, AIDS 
encephalopathy, 
Bell's palsy, 
progressive 
multifocal 
leukoencephalopathy, 
primary CNS 
lymphoma, stroke, 
transverse myelitis, 
HIV-associated 
peripheral 
neuropathy, 
inflammatory 
demyelinating 
polyneuropathy, 
immune 
reconstitution 
inflammatory 
syndrome and 
vacuolar myelopathy
• Asymptomatic 
neurocognitive 
impairment, mild 
neurocognitive 
disorder and HIV-
associated 
dementia
Delirium, major 
depression, bipolar 
disorder (including 
AIDS mania), 
schizophrenia, 
substance abuse or 
dependence and post-
traumatic stress 
disorder
Cryptococcal meningitis Global, greatest 
burden in sub-
Saharan Africa 
and Asia
Annual 
incidence 
estimate: 
957,900 in 
2009, 
approximately 
624,700 deaths 
annually
• Headache, 
meningismus, 
intracranial 
hypertension, mental 
status changes, focal 
intracerebral 
granulomas 
(cryptococcomas), 
hydrocephalus 
(communicating and 
non-communicating), 
papilledema, 
sensorineural 
deafness, cranial 
nerve palsies, motor 
• Mimicking of 
vascular 
dementia, and 
reversible 
dementia
Personality change, 
confusional psychosis 
and mania
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Infectious disease Regions affected Estimated 
prevalence or 
annual 
incidence of 
infection
Health consequences
Neurological Cognitive Mental health
and sensory deficits, 
cerebellar 
dysfunction and 
seizures
Toxoplasma encephalitis Global, greatest 
burden in sub-
Saharan Africa 
and Asia
No reliable 
global estimates 
of incidence of 
toxoplasma 
encephalitis, but 
toxoplasma 
infection is 
present in 14% 
of the 
population in 
the United 
States, 
compared with 
23-47% in some 
European, Latin 
American and 
African 
countries
• Headache, focal 
neurological deficit, 
seizures and altered 
mental status
• Dementia Schizophrenia and 
behaviour disorders
BACTERIAL
Neonatal sepsis and 
meningitis
Global Annual 
incidence 
estimates for 
south Asia, sub-
Saharan Africa 
and Latin 
America: 
neonatal sepsis, 
1.7 million 
(uncertainty 
estimate, 1.1-2.4 
million); 
neonatal 
meningitis, 
200,000; 95% 
CI, 
21,000-350,000)
• Little data for 
neonatal sepsis 
globally, especially 
among those more 
than 32 weeks 
gestation or more 
than 1,500g
• 23% (95% CI, 
19-26%) of neonatal 
meningitis survivors 
(or 18,000 children; 
95% CI, 
2,700-35,000) 
estimated to sustain 
moderate to severe 
neurodevelopmental 
impairment
• In sepsis or 
meningitis, the 
primary neurological 
sequelae are cerebral 
palsy, impairment to 
vision, hearing and 
motor function, and 
seizure disorders
• Limited studies 
reporting 
cognitive 
impairment; 
developmental 
delay or learning 
difficulties are 
frequent in sepsis 
(30.0%; IQR, 
26.4-44.4%) and 
meningitis 
(33.3%; IQR, 
26.7-36.8%)
No data
Bacterial meningitis Global Annual 
incidence 
estimate: 1.2 
million
• 22.8% (IQR, 
12.1-29.2%) have at 
least 1 neurocognitive 
sequela at discharge, 
19.9% (IQR, 
12.1-35.2%) have at 
least 1 sequela post-
discharge; 16.0% 
(IQR, 7.1-21.2%) 
have at least 1 major 
sequela at discharge, 
12.8% (iQr, 
7.1-21.1%) have at 
least 1 major sequela 
post discharge
• Neurological 
sequelae include 
motor deficits, 
• In children, 
cognitive 
impairment 
including low IQ, 
academic 
limitations, and 
impared executive 
function and in 
adults, cognitive 
impairment with 
slower cognitive 
speed seen
Behavioural changes 
and emotional 
disturbance including 
ADHD and learning 
difficulties
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Infectious disease Regions affected Estimated 
prevalence or 
annual 
incidence of 
infection
Health consequences
Neurological Cognitive Mental health
hearing loss and 
visual disturbances
• Risk of major 
sequelae is higher in 
Africa (25.1%) and 
southeast Asia 
(21.6%) compared 
with Europe (9.4%)
Tuberculous meningitis 
(also an opportunistic 
infection in HIV)
Global, most 
burden in sub-
Saharan Africa 
and Asia
No reliable 
global incidence 
estimates; 
highest in 
countries with 
high prevalence 
of HIV infection
• Neurological 
sequelae in 53.9% of 
child survivors (95% 
CI, 42.6-64.9)
• Gross and fine 
motor impairment in 
children
• Motor deficits, optic 
atrophy, 
ophthalmoplegia, and 
hearing impairment in 
adults and older 
children
• Cognitive 
impairment in all 
areas tested, and 
poor scholastic 
progress
Emotional disturbance
Neurosyphilis Global No reliable 
global incidence 
estimates; most 
cases occur in 
HIV-positive 
individuals
• Meningitis, 
cerebrovascular 
infarction, and 
paresis, tabes dorsalis 
(ataxia, paraesthesia 
and bladder 
dysfunction)
• Impaired 
memory, 
disorientation and 
dementia
Dementia, depression, 
delirium, mania and 
psychosis
PARASITIC
Neurocysticercosis Global, greatest 
burden in pig-
raising areas with 
poor sanitation
2010 prevalence 
estimate: 1.4 
million (95% 
CI, 1.3-1.6 
million) 
(epilepsy only)
• Among people with 
symptomatic 
neurocysticercosis 
diagnosed with brain 
imaging: seizures and 
epilepsy (78.8%; 95% 
CI, 65.1-89.7%), 
headaches (37.9%; 
95% CI, 23.3-53.7%), 
focal deficits (16.0%; 
95% CI, 9.7-23.6%) 
and symptoms 
associated with 
increased intracranial 
pressure (11.7%; 95% 
CI, 6.0-18.9%)
• Case reports of 
cognitive decline
• Cognitive 
symptoms of 
neurocysticercosis 
with active cysts: 
affects naming, 
verbal fluency and 
non-verbal 
memory
Neurocysticercosis 
with active cysts: 
dementia (12.5%) and 
cognitive impairment, 
but not dementia 
(27.5%); psychosis
Malaria Sub-Saharan 
Africa, Latin 
America, Asia 
and Oceania
Annual 
incidence 
estimate: 216 
million
• Cerebral malaria: 
5-28% of children 
have neurological 
deficits on discharge, 
including epilepsy, 
acute hemiparesis, 
hypertonia, cortical 
blindness and ataxia
• By 6-month follow-
up the percentage of 
children with deficits 
has decreased to 
0-4.4%, primarily in 
the areas of gross 
motor and fine motor 
skills
• Uncomplicated 
malaria: motor skills
• Cerebral malaria 
affects general 
cognition, 
attention, working 
memory, visual 
spatial skills, 
somatosensory 
discrimination, 
speech and 
language, and 
receptive and 
expressive 
language
• Thirteen IQ 
point difference 
from non-affected 
children 1 year 
after episode, and 
around 26% of 
children have 
Cerebral malaria: 
internalizing and 
externalizing 
problems, ADHD, 
disruptive behaviour, 
psychosis and 
depression
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Infectious disease Regions affected Estimated 
prevalence or 
annual 
incidence of 
infection
Health consequences
Neurological Cognitive Mental health
impairment 2 
years after
• Severe malaria 
with neurological 
involvement 
affects executive 
function
• Severe malarial 
anaemia affects 
overall cognition 
estimated to lead 
to the equivalent 
of an 11 IQ point 
difference from 
non-affected 
community 
children
• Malaria with 
multiple seizures 
leads to speech 
and language 
problems
• Malaria with 
impaired 
consciousness 
leads to attention/
language 
problems
• Uncomplicated 
malaria leads to 
language 
problems
• Asymptomatic 
malaria leads to 
problems with 
fine motor 
coordination, 
attention and 
abstract reasoning
STH infection Global, greatest 
burden in sub-
Saharan Africa 
and Southeast 
Asia
Estimated 2010 
prevalence: 
hookworm 
infected 439 
million (95% 
CI, 406-480), 
Ascaris 
lumbricoides 
infected 819 
million (95% 
CI, 772-892) 
and Trichuris 
trichiura 
infected 465 
million (95% 
CI, 430-508).
• Not described • School-aged 
children: T. 
trichiura and A. 
lumbricoides 
affected learning 
and verbal 
memory in one 
study
• In another, 
general STH 
infection reduced 
memory capacity, 
rate of processing 
and attention
Children under 5 
years of age: social 
and emotional 
disturbances 
(combined with 
anaemia)
Schistosomiasis Global, greatest 
in sub-Saharan 
Africa and 
Southeast Asia
Estimated 2010 
prevalence: 252 
million infected
• Acute schistosomal 
encephalopathy: 
headache, confusion, 
seizure, loss of 
consciousness, focal 
deficits, visual 
impairment and 
ataxia
• Cerebral 
schistosomiasis: 
headaches, motor 
deficits, visual 
abnormalities, 
seizures, altered 
• For Schistosoma 
japonicum 
infection in 
children (not 
neurological 
infection): verbal 
memory and 
verbal fluency 
affected
No data
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Infectious disease Regions affected Estimated 
prevalence or 
annual 
incidence of 
infection
Health consequences
Neurological Cognitive Mental health
mental status, vertigo, 
sensory impairment, 
speech disturbances 
and ataxia
• Spinal cord 
schistosomiasis: 
lower limb weakness, 
bladder dysfunction, 
lower limb 
paraesthesia, 
hypoaesthesia/
anaesthesia, deep 
tendon reflex 
abnormalities, 
constipation and 
impotence in 80% of 
cases
ADHD, attention deficit disorder; CI, confidence interval; CNS, central nervous system; HSV, herpes simplex virus; IQR, interquartile range; 
LMICs, low- and middle-income countries; PNS, peripheral nervous system; STH, soil-transmitted helminths; VZV, varicella-zoster virus. 
Prevalence estimates are typically used (for example, STH infections and schistosomiasis) because accurate incidence numbers for these infections 
are difficult to obtain.
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Table 2
Potential areas for intervention in infectious diseases that affect the nervous system.
Disease Vaccine available Control of zoonotic 
reservoirs
Control of 
vector 
populations
Treatment
VIRAL
Dengue New dengue vaccines being tested 
in large field trials
NA Yes None available
Chikungunya No NA Yes None available
Japanese encephalitis Yes No Yes None available
Rabies Yes Yes NA None available
HSV encephalitis No NA NA Yes
VZV Yes NA NA Yes
Congenital cytomegalovirus No NA NA Yes
HIV-related
HIV No NA NA Yes
Cryptococcal meningitis No NA NA Yes
Toxoplasma encephalitis No Yes NA Yes
BACTERIAL
Neonatal sepsis and meningitis No NA NA Yes
Bacterial meningitis Yes, for Haemophilus influenzae 
type b, and pneumococcal (multiple 
serotypes) and meningococcal (A, 
C, Y and W135) meningitis
NA NA Yes
Tuberculous meningitis Partial protection provided by BCG 
vaccination
Infrequent (cases due to 
Mycobacterium bovid and 
Mycobacterium caprae, 
both of which are present in 
cattle, reported)
NA Yes
Neurosyphilis No NA NA Yes
PARASITIC
Neurocysticercosis No Porcine vaccine trials 
underway, pig treatment 
available
NA Yes
Malaria RTS,S vaccine had efficacy in phase 
III studies and other vaccines are 
being developed
NA except for Plasmodium 
knowlesi
Yes Yes
STH No. Hookworm vaccine is in phase I 
trials, but is linked to adverse events
NA except for Toxocara 
canis
NA Yes
Schistosomiasis No, but phase I vaccine trials are 
ongoing
Bovine vaccine trials 
underway for Schistosoma 
japonicum
Yes Yes
BCG, Bacillus Calmette-Guerin; HSV, herpes simplex virus; NA, not applicable; STH, soil-transmitted helminth; VZV, varicella-zoster virus.
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Table 3
Global research for infections that affect the nervous system.
Priority area Research needed
Diagnosis • Rapid, accurate, low-cost, point-of-care diagnostic tests for infections that affect the nervous system
• Clinical diagnostic algorithms for infections that affect the nervous system
• Improved testing for detection of infection-related nervous-system disabilities
Epidemiology • Accurate incidence and prevalence estimates of common infections that affect the nervous system
• Accurate identification and frequency estimates of nervous-system manifestations and sequelae
• Identification of potentially modifiable risk factors specific to infections that affect the nervous system
Pathogenesis • Identification of host response pathways that lead to nervous-system deficits or to clinical immunity
• Identification of pathogen factors that lead to nervous-system deficits or to clinical immunity
• Assessment of risks and interactions of co-infections and co-morbidity
Vaccine development • Develop safe and effective vaccines based on immunology, epidemiology and pathogenesis studies
• Phase I and II trials
• Phase III trials
Treatment • Effective adjunctive treatment to prevent or decrease nervous-system deficits or disabilities
• Low cost, low toxicity antimicrobials that work against drug-resistant pathogens
• Multi-site, large clinical trials that provide definitive answers on interventions
• Effective or improved primary treatment of infection
Rehabilitation • Effective and feasible physical, occupational and cognitive rehabilitation programmes
Operations and implementation • Optimal methods to implement or operationalize interventions with known efficacy
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